查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1971244

人工智慧在動物醫藥研發市場分析及預測（至2035年）：依類型、產品類型、服務、技術、應用、組件、最終用戶、實施類型、開發階段及解決方案分類

AI in Veterinary Drug Discovery Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, Component, End User, Deployment, Stage, Solutions
出版日期: | 出版商: Global Insight Services | 英文 331 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

預計到2034年，人工智慧在動物醫藥研發領域的市場規模將從2024年的15億美元成長至58億美元，複合年成長率約為14.5%。該市場利用人工智慧技術提高動物健康藥物研發的效率和精準度。其涵蓋的AI驅動平台能夠簡化標靶辨識、先導化合物動物醫藥動物醫藥的不斷成長，人工智慧技術對於縮短藥物上市時間和提高藥物發現過程的精確度至關重要，從而推動動物健康解決方案的進步。

在對高效創新藥物研發流程的需求驅動下，人工智慧在動物醫藥研發領域的市場正迅速發展。其中，機器學習演算法表現最為突出，它透過最佳化結果預測和化合物篩選，徹底革新了藥物發現流程。深度學習模型尤其在該領域發揮重要作用，能夠深入洞察複雜的生物數據。自然語言處理（NLP）緊隨其後，它透過從海量科學文獻中提取有用資訊來增強數據分析。 NLP簡化研究流程的能力對於加速藥物發現至關重要。在眾多細分領域中，化合物篩檢表現最為突出，它利用人工智慧技術更精準地識別有前景的候選藥物。其次是藥物重定位，它透過發現現有藥物的新用途，提供更具成本效益的解決方案。這些進展凸顯了人工智慧在獸醫學領域的變革潛力，並有望顯著提高藥物療效和研發速度。

市場區隔
類型 機器學習、深度學習、自然語言處理、電腦視覺
產品 軟體工具、人工智慧平台和人工智慧服務
服務 諮詢、整合和實施、支援和維護
科技 基於雲端、本地、混合和邊緣的人工智慧
應用 藥物發現、診斷、精準醫療、臨床試驗
成分 硬體、軟體和服務
最終用戶 研究機構、製藥公司、生技公司、獸醫診所、學術機構
實施表格 雲端、本地部署、混合部署
步 藥物發現、臨床前研究、臨床研究、核准、上市後監測
解決方案 預測分析、影像識別、基因體學、蛋白質體學

市場概況：

隨著新興企業取得顯著進展，動物醫藥研發領域的人工智慧市場佔有率正經歷動態變化。定價環境競爭激烈，反映了創新與可負擔性之間的平衡。在技​​術進步和對高效藥物發現流程日益成長的需求推動下，新產品頻繁上市。該市場擁有強大的人工智慧驅動解決方案儲備，這些方案能夠提升藥物發現和開發能力。競爭基準研究顯示，市場參與者類型多元，既有老牌製藥巨頭，也有敏捷的Start-Ups。監管影響至關重要，北美和歐洲的嚴格指導方針塑造了競爭格局。此外，政府為促進人工智慧在獸醫領域的應用而採取的措施也對市場產生影響。隨著企業尋求獲得競爭優勢，策略夥伴關係和合作日益增加。市場前景樂觀，人工智慧技術可望徹底改變動物醫藥研發，為成長和創新帶來前所未有的機會。

主要趨勢和促進因素：

受技術進步和對創新獸藥日益成長的需求驅動，人工智慧在動物醫藥研發領域的市場正經歷強勁成長。一個關鍵趨勢是將人工智慧與巨量資料分析相結合，從而高效識別潛在化合物並加速藥物發現過程。人工智慧驅動的平台能夠精準預測藥物的療效和安全性，減少對傳統試驗法的依賴。此外，個人化獸藥的日益普及促使人們利用人工智慧工具開發物種和疾病特異性藥物，從而改善治療效果和動物福利。另一個促進因素是，由於通用感染疾病發病率的上升，對快速藥物研發的需求日益成長。獸醫行業正擴大採用人工智慧來簡化監管合規流程並加快核准速度。此外，科技公司與動物醫藥生產商之間的合作也正在推動創新。在動物健康領域，尤其是在獸醫基礎設施仍在發展中的新興市場，開發人工智慧解決方案以滿足尚未滿足的需求存在著許多機會。

限制與挑戰：

人工智慧在動物醫藥研發領域的應用面臨許多顯著的限制與挑戰。其中一個主要限制因素是人工智慧技術實施高成本，這可能成為中小企業和Start-Ups的一大障礙。這項經濟壁壘限制了人工智慧解決方案在動物醫藥研發領域的創新和廣泛應用。此外，同時具備人工智慧和獸醫學專業知識的熟練人才短缺。這種技能缺口阻礙了人工智慧驅動型解決方案的開發和整合。另一個挑戰是監管環境，通常複雜且在不同地區差異顯著，導致產品開發和市場准入的延遲。資料隱私和安全問題也構成挑戰。處理敏感資料需要強大的系統來防止資料外洩。最後，缺乏在動物醫藥研發中實施人工智慧的標準化通訊協定可能導致結果不一致，進一步限制了市場的成長潛力。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 機器學習
    • 深度學習
    • 自然語言處理
    • 電腦視覺
  • 市場規模及預測：依產品分類
    • 軟體工具
    • 人工智慧平台
    • 人工智慧服務
  • 市場規模及預測：依服務分類
    • 諮詢
    • 整合與部署
    • 支援與維護
  • 市場規模及預測：依技術分類
    • 基於雲端的
    • 本地部署
    • 混合
    • 邊緣人工智慧
  • 市場規模及預測：依應用領域分類
    • 藥物發現
    • 診斷
    • 精準醫療
    • 臨床試驗
  • 市場規模及預測：依組件分類
    • 硬體
    • 軟體
    • 服務
  • 市場規模及預測：依最終用戶分類
    • 研究所
    • 製藥公司
    • 生技公司
    • 獸醫診所
    • 學術機構
  • 市場規模及預測：依發展狀況
    • 雲
    • 本地部署
    • 混合
  • 市場規模及預測：依階段分類
    • 發現
    • 臨床前階段
    • 臨床
    • 核准
    • 上市後監測
  • 市場規模及預測：按解決方案分類
    • 預測分析
    • 影像識別
    • 基因組學
    • 蛋白質體學

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章：公司簡介

  • Insilico Medicine
  • Atomwise
  • Cyclica
  • Deep Genomics
  • BenevolentAI
  • Exscientia
  • Healx
  • Valo Health
  • Standigm
  • twoXAR
  • Aitia
  • Numerate
  • Aria Pharmaceuticals
  • BioSymetrics
  • Verge Genomics

第9章：關於我們

簡介目錄
Product Code: GIS33591

AI in Veterinary Drug Discovery Market is anticipated to expand from $1.5 billion in 2024 to $5.8 billion by 2034, growing at a CAGR of approximately 14.5%. The AI in Veterinary Drug Discovery Market leverages artificial intelligence to enhance the efficiency and accuracy of drug development for animal health. This market encompasses AI-driven platforms that streamline target identification, lead optimization, and predictive modelling. With the rising demand for innovative veterinary therapeutics, AI technologies are pivotal in reducing time-to-market and enhancing the precision of drug discovery processes, fostering advancements in animal healthcare solutions.

The AI in Veterinary Drug Discovery Market is evolving rapidly, driven by the need for efficient and innovative drug development processes. The machine learning algorithms segment is the top performer, revolutionizing drug discovery by predicting outcomes and optimizing compound selection. Within this segment, deep learning models are particularly impactful, providing nuanced insights into complex biological data. The second highest performing segment is natural language processing (NLP), which enhances data analysis by extracting valuable information from vast scientific literature. NLP's ability to streamline research is crucial for accelerating drug discovery timelines. In terms of sub-segments, the compound screening sub-segment leads in performance, leveraging AI to identify promising drug candidates with higher precision. The drug repurposing sub-segment follows, offering cost-effective solutions by finding new uses for existing drugs. Together, these advancements underscore the transformative potential of AI in veterinary medicine, promising significant improvements in drug efficacy and development speed.

Market Segmentation
TypeMachine Learning, Deep Learning, Natural Language Processing, Computer Vision
ProductSoftware Tools, AI Platforms, AI Services
ServicesConsulting, Integration and Deployment, Support and Maintenance
TechnologyCloud-based, On-premises, Hybrid, Edge AI
ApplicationDrug Discovery, Diagnostics, Precision Medicine, Clinical Trials
ComponentHardware, Software, Services
End UserResearch Institutes, Pharmaceutical Companies, Biotechnology Firms, Veterinary Clinics, Academic Institutions
DeploymentCloud, On-premise, Hybrid
StageDiscovery, Preclinical, Clinical, Approval, Post-market Surveillance
SolutionsPredictive Analytics, Image Recognition, Genomics, Proteomics

Market Snapshot:

The AI in Veterinary Drug Discovery Market is witnessing a dynamic shift in market share, with emerging players making significant inroads. The pricing landscape remains competitive, reflecting the balance between innovation and affordability. New product launches are frequent, driven by technological advancements and the growing demand for efficient drug discovery processes. The market is characterized by a robust pipeline of AI-driven solutions, offering enhanced capabilities in drug discovery and development. Competition benchmarking reveals a diverse array of players, ranging from established pharmaceutical giants to nimble startups. Regulatory influences are pivotal, with stringent guidelines in North America and Europe shaping the competitive landscape. The market is further influenced by government initiatives promoting AI integration in veterinary sciences. As companies strive to gain a competitive edge, strategic partnerships and collaborations are on the rise. The market outlook is optimistic, with AI technologies poised to revolutionize veterinary drug discovery, offering unprecedented opportunities for growth and innovation.

Geographical Overview:

The AI in veterinary drug discovery market is witnessing substantial growth across various regions, each exhibiting unique characteristics. North America leads the charge, propelled by advanced AI technologies and significant investments in veterinary research. The region's robust infrastructure and strong collaborations between tech firms and veterinary institutions are key drivers. Europe is making strides with a focus on innovation and sustainability in veterinary drug development. The region's regulatory environment and emphasis on animal welfare encourage the adoption of AI-driven solutions. Asia Pacific is emerging as a promising market, driven by a surge in pet ownership and rising demand for veterinary care. Countries like China and India are investing heavily in AI technologies, fostering a dynamic ecosystem for veterinary drug discovery. Latin America and the Middle East & Africa are nascent markets with growing potential. These regions are recognizing AI's transformative role in enhancing veterinary healthcare, paving the way for future growth.

Key Trends and Drivers:

The AI in Veterinary Drug Discovery Market is experiencing robust growth. This is driven by technological advancements and increasing demand for innovative veterinary therapeutics. Key trends include the integration of AI with big data analytics, which accelerates drug discovery processes by identifying potential compounds more efficiently. AI-driven platforms are enabling precise predictions of drug efficacy and safety, reducing the reliance on traditional trial-and-error methods. Moreover, there is a growing emphasis on personalized veterinary medicine, where AI tools are tailored to develop species-specific and condition-specific drugs. This enhances treatment outcomes and animal welfare. Another driver is the rising incidence of zoonotic diseases, prompting the need for rapid drug development. The veterinary sector is increasingly adopting AI to streamline regulatory compliance and expedite the approval process. Additionally, partnerships between tech companies and veterinary pharmaceutical firms are fostering innovation. Opportunities abound in developing AI solutions that address unmet needs in animal health, particularly in emerging markets where veterinary infrastructure is evolving.

Restraints and Challenges:

The AI in Veterinary Drug Discovery Market encounters several notable restraints and challenges. A significant restraint is the high cost of AI technology deployment, which can be prohibitive for smaller firms and startups. This financial barrier limits innovation and the widespread adoption of AI solutions in veterinary drug discovery. Additionally, there is a scarcity of skilled professionals with expertise in both AI and veterinary sciences. This skill gap hampers the development and integration of AI-driven solutions. Another challenge is the regulatory landscape, which is often complex and varies significantly across regions, leading to delays in product development and market entry. Data privacy and security concerns also pose challenges, as the handling of sensitive data requires robust systems to prevent breaches. Lastly, the lack of standardized protocols for AI implementation in veterinary drug discovery can lead to inconsistent outcomes, further complicating the market's growth potential.

Key Players:

Insilico Medicine, Atomwise, Cyclica, Deep Genomics, BenevolentAI, Exscientia, Healx, Valo Health, Standigm, twoXAR, Aitia, Numerate, Aria Pharmaceuticals, BioSymetrics, Verge Genomics

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by Component
  • 2.7 Key Market Highlights by End User
  • 2.8 Key Market Highlights by Deployment
  • 2.9 Key Market Highlights by Stage
  • 2.10 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Machine Learning
    • 4.1.2 Deep Learning
    • 4.1.3 Natural Language Processing
    • 4.1.4 Computer Vision
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Software Tools
    • 4.2.2 AI Platforms
    • 4.2.3 AI Services
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Consulting
    • 4.3.2 Integration and Deployment
    • 4.3.3 Support and Maintenance
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Cloud-based
    • 4.4.2 On-premises
    • 4.4.3 Hybrid
    • 4.4.4 Edge AI
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Drug Discovery
    • 4.5.2 Diagnostics
    • 4.5.3 Precision Medicine
    • 4.5.4 Clinical Trials
  • 4.6 Market Size & Forecast by Component (2020-2035)
    • 4.6.1 Hardware
    • 4.6.2 Software
    • 4.6.3 Services
  • 4.7 Market Size & Forecast by End User (2020-2035)
    • 4.7.1 Research Institutes
    • 4.7.2 Pharmaceutical Companies
    • 4.7.3 Biotechnology Firms
    • 4.7.4 Veterinary Clinics
    • 4.7.5 Academic Institutions
  • 4.8 Market Size & Forecast by Deployment (2020-2035)
    • 4.8.1 Cloud
    • 4.8.2 On-premise
    • 4.8.3 Hybrid
  • 4.9 Market Size & Forecast by Stage (2020-2035)
    • 4.9.1 Discovery
    • 4.9.2 Preclinical
    • 4.9.3 Clinical
    • 4.9.4 Approval
    • 4.9.5 Post-market Surveillance
  • 4.10 Market Size & Forecast by Solutions (2020-2035)
    • 4.10.1 Predictive Analytics
    • 4.10.2 Image Recognition
    • 4.10.3 Genomics
    • 4.10.4 Proteomics

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 Component
      • 5.2.1.7 End User
      • 5.2.1.8 Deployment
      • 5.2.1.9 Stage
      • 5.2.1.10 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 Component
      • 5.2.2.7 End User
      • 5.2.2.8 Deployment
      • 5.2.2.9 Stage
      • 5.2.2.10 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 Component
      • 5.2.3.7 End User
      • 5.2.3.8 Deployment
      • 5.2.3.9 Stage
      • 5.2.3.10 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 Component
      • 5.3.1.7 End User
      • 5.3.1.8 Deployment
      • 5.3.1.9 Stage
      • 5.3.1.10 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 Component
      • 5.3.2.7 End User
      • 5.3.2.8 Deployment
      • 5.3.2.9 Stage
      • 5.3.2.10 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 Component
      • 5.3.3.7 End User
      • 5.3.3.8 Deployment
      • 5.3.3.9 Stage
      • 5.3.3.10 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 Component
      • 5.4.1.7 End User
      • 5.4.1.8 Deployment
      • 5.4.1.9 Stage
      • 5.4.1.10 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 Component
      • 5.4.2.7 End User
      • 5.4.2.8 Deployment
      • 5.4.2.9 Stage
      • 5.4.2.10 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 Component
      • 5.4.3.7 End User
      • 5.4.3.8 Deployment
      • 5.4.3.9 Stage
      • 5.4.3.10 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 Component
      • 5.4.4.7 End User
      • 5.4.4.8 Deployment
      • 5.4.4.9 Stage
      • 5.4.4.10 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 Component
      • 5.4.5.7 End User
      • 5.4.5.8 Deployment
      • 5.4.5.9 Stage
      • 5.4.5.10 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 Component
      • 5.4.6.7 End User
      • 5.4.6.8 Deployment
      • 5.4.6.9 Stage
      • 5.4.6.10 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 Component
      • 5.4.7.7 End User
      • 5.4.7.8 Deployment
      • 5.4.7.9 Stage
      • 5.4.7.10 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 Component
      • 5.5.1.7 End User
      • 5.5.1.8 Deployment
      • 5.5.1.9 Stage
      • 5.5.1.10 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 Component
      • 5.5.2.7 End User
      • 5.5.2.8 Deployment
      • 5.5.2.9 Stage
      • 5.5.2.10 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 Component
      • 5.5.3.7 End User
      • 5.5.3.8 Deployment
      • 5.5.3.9 Stage
      • 5.5.3.10 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 Component
      • 5.5.4.7 End User
      • 5.5.4.8 Deployment
      • 5.5.4.9 Stage
      • 5.5.4.10 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 Component
      • 5.5.5.7 End User
      • 5.5.5.8 Deployment
      • 5.5.5.9 Stage
      • 5.5.5.10 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 Component
      • 5.5.6.7 End User
      • 5.5.6.8 Deployment
      • 5.5.6.9 Stage
      • 5.5.6.10 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 Component
      • 5.6.1.7 End User
      • 5.6.1.8 Deployment
      • 5.6.1.9 Stage
      • 5.6.1.10 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 Component
      • 5.6.2.7 End User
      • 5.6.2.8 Deployment
      • 5.6.2.9 Stage
      • 5.6.2.10 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 Component
      • 5.6.3.7 End User
      • 5.6.3.8 Deployment
      • 5.6.3.9 Stage
      • 5.6.3.10 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 Component
      • 5.6.4.7 End User
      • 5.6.4.8 Deployment
      • 5.6.4.9 Stage
      • 5.6.4.10 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 Component
      • 5.6.5.7 End User
      • 5.6.5.8 Deployment
      • 5.6.5.9 Stage
      • 5.6.5.10 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Insilico Medicine
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Atomwise
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Cyclica
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Deep Genomics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 BenevolentAI
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Exscientia
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Healx
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Valo Health
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Standigm
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 twoXAR
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Aitia
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Numerate
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Aria Pharmaceuticals
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 BioSymetrics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Verge Genomics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us